Livzon Pharmaceutical Group (SZSE:000513) Cash-to-Debt : 3.15 (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Livzon Pharmaceutical Group Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Livzon Pharmaceutical Group's cash to debt ratio for the quarter that ended in Mar. 2024 was 3.15.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Livzon Pharmaceutical Group could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Livzon Pharmaceutical Group's Cash-to-Debt or its related term are showing as below:

SZSE:000513' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62 Med: 3.65 Max: 19458.86
Current: 3.15

During the past 13 years, Livzon Pharmaceutical Group's highest Cash to Debt Ratio was 19458.86. The lowest was 0.62. And the median was 3.65.

SZSE:000513's Cash-to-Debt is ranked better than
66.79% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs SZSE:000513: 3.15

Livzon Pharmaceutical Group Cash-to-Debt Historical Data

The historical data trend for Livzon Pharmaceutical Group's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Livzon Pharmaceutical Group Cash-to-Debt Chart

Livzon Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

6.52

5.17

3.46

2.91

2.75

Livzon Pharmaceutical Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															2.71	2.57	2.60	2.75	3.15

Competitive Comparison of Livzon Pharmaceutical Group's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Livzon Pharmaceutical Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Livzon Pharmaceutical Group's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Livzon Pharmaceutical Group's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Livzon Pharmaceutical Group's Cash-to-Debt falls into.

Livzon Pharmaceutical Group Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Livzon Pharmaceutical Group's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11407.516	/	(2519.689	+	1621.804)
	=	2.75

Livzon Pharmaceutical Group's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11231.003	/	(2699.875	+	864.402)
	=	3.15

Livzon Pharmaceutical Group (SZSE:000513) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Livzon Pharmaceutical Group Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Livzon Pharmaceutical Group's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Livzon Pharmaceutical Group (SZSE:000513) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Livzon Pharmaceutical Group Inc (SZSE:000513) » Definitions » Cash-to-Debt

Traded in Other Exchanges

01513:Hong Kong LP6:Germany

Address

38 Chuangye North Road, Headquarters Building, Jinwan District, Guangdong Province, Zhuhai, CHN, 519090

Website

https://www.livzon.com.cn

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment which is pharmaceutical manufacturing.

Livzon Pharmaceutical Group (SZSE:000513) Headlines

No Headlines